600056 中国医药
2025/06 - 中期
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
经营活动产生之现金流量净额(546,133)1,005,431859,0751,645,872148,421
投资活动产生之现金流量净额(101,566)(367,657)(316,247)22,139(254,455)
筹资活动产生之现金流量净额(724,971)(258,234)(725,654)(2,024)(729,189)
汇率变动对现金及现金等价物的影响(1,025)1,7802,04110,742(4,054)
现金及现金等价物净增加/(减少)(1,373,694)381,320(180,785)1,676,730(839,277)
期初现金及现金等价物余额3,857,1503,330,2593,511,0441,834,3142,673,591
期末现金及现金等价物余额2,483,4563,711,5793,330,2593,511,0441,834,314